MA40470A - Composés et procédés d'inhibition des histones déméthylases - Google Patents
Composés et procédés d'inhibition des histones déméthylasesInfo
- Publication number
- MA40470A MA40470A MA040470A MA40470A MA40470A MA 40470 A MA40470 A MA 40470A MA 040470 A MA040470 A MA 040470A MA 40470 A MA40470 A MA 40470A MA 40470 A MA40470 A MA 40470A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- inhibiting histone
- histone demethylases
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/48—Aldehydo radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La présente demande concerne des composés de formule (i), (ii), (iii), (iv), (v), (vi), (iiia), (iiib), (iiic), (hid), (hie), (iiif), et (iiig). Les composés de formule (i) ont la structure : dans laquelle r
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462042717P | 2014-08-27 | 2014-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40470A true MA40470A (fr) | 2016-03-03 |
Family
ID=54062822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040470A MA40470A (fr) | 2014-08-27 | 2015-08-26 | Composés et procédés d'inhibition des histones déméthylases |
Country Status (16)
Country | Link |
---|---|
US (1) | US9802941B2 (fr) |
EP (1) | EP3186238A1 (fr) |
JP (1) | JP2017526675A (fr) |
KR (1) | KR20170040805A (fr) |
CN (1) | CN107074807A (fr) |
AR (1) | AR101692A1 (fr) |
AU (1) | AU2015306662A1 (fr) |
BR (1) | BR112017003442A2 (fr) |
CA (1) | CA2957947A1 (fr) |
EA (1) | EA201790154A1 (fr) |
IL (1) | IL250355A0 (fr) |
MA (1) | MA40470A (fr) |
MX (1) | MX2017002451A (fr) |
SG (1) | SG11201701182VA (fr) |
TW (1) | TW201625536A (fr) |
WO (1) | WO2016033169A1 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017198785A1 (fr) * | 2016-05-18 | 2017-11-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Dérivés d'oxime utiles en tant qu'inhibiteurs de l'histone déméthylase kdm4c |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
KR102202984B1 (ko) | 2016-05-27 | 2021-01-13 | 길리애드 사이언시즈, 인코포레이티드 | Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
TW202402300A (zh) | 2017-01-31 | 2024-01-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018222831A1 (fr) * | 2017-05-31 | 2018-12-06 | The Children's Medical Center Corporation | Ciblage de la lysine déméthylase (kdms) en tant que stratégie thérapeutique destinée au lymphome diffus à grandes cellules b |
CA3084582A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucleotides 2'3' cycliques ayant une liaison phosphonate activant la proteine adaptatrice de sting |
WO2019123340A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
WO2019154261A1 (fr) * | 2018-02-09 | 2019-08-15 | 南京明德新药研发股份有限公司 | Dérivé de pyridine lié à la voie kmd5 |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
EP3759109B1 (fr) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b |
WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチド |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
CA3093130C (fr) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Inhibiteurs pd-1/pd-l1 |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
JP2021534084A (ja) * | 2018-08-06 | 2021-12-09 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | ヒストンデメチラーゼ5阻害剤およびその使用 |
KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
EP3934757B1 (fr) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3972695A1 (fr) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
CA3142513A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Proteines de fusion flt3l-fc et procedes d'utilisation |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (fr) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
CR20220129A (es) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
CA3169348A1 (fr) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Promedicaments de nucleosides de 4'-c-substitue-2-halo-2'-desoxyadenosine et leurs procedes de fabrication et d'utilisation |
US20220119426A1 (en) | 2020-08-07 | 2022-04-21 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CN114907317B (zh) * | 2022-06-01 | 2023-06-13 | 郑州大学 | 一种吡唑-乙烯基-异烟酸衍生物及其制备方法和应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
WO1998008849A1 (fr) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede |
AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
EP1367057B1 (fr) | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones E et F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
EP1058679B1 (fr) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthese d'epothilones, de leurs intermediaires et de leurs analogues |
KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
AU2007265368A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
EP2350051A4 (fr) | 2008-10-29 | 2012-05-30 | Sirtris Pharmaceuticals Inc | Pyridine, pyridine bicyclique et analogues associés en tant que modulateurs de sirtuine |
EP2461835A4 (fr) | 2009-08-07 | 2013-05-15 | Wistar Inst | Composition contenant des inhibiteurs de jarid1b et méthodes de traitement du cancer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
MX347851B (es) * | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
WO2011130661A1 (fr) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp) |
EP2578569B1 (fr) | 2010-05-27 | 2015-10-28 | ASKA Pharmaceutical Co., Ltd. | Composé hétérocyclique et antagoniste du récepteur h1 |
WO2012007007A1 (fr) * | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibiteurs de hdme |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012071469A2 (fr) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Inhibiteurs d'histone déméthylase et utilisations de ceux-ci pour le traitement de cancer |
EP2688568B1 (fr) | 2011-03-25 | 2019-06-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
HUE050962T2 (hu) | 2011-08-15 | 2021-01-28 | Univ Utah Res Found | Hiszton demetiláz inhibitor szubsztituált (E)-N'-(1-feniletilidén)-benzohidrazid származékok |
CN102585150B (zh) | 2012-02-01 | 2013-09-04 | 嘉兴学院 | 织物涂饰用阴离子水性聚氨酯分散体的制备方法 |
WO2013123411A1 (fr) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Procédés de diagnostic et de traitement du cancer |
SI3023415T1 (en) | 2012-10-02 | 2018-01-31 | Gilead Sciences, Inc. | Histone demethylase inhibitors |
CA2894399A1 (fr) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Inhibiteurs de l'histone demethylase |
LT2934145T (lt) | 2012-12-19 | 2018-02-26 | Celgene Quanticel Research, Inc. | Histono demetilazės inhibitoriai |
ES2718495T3 (es) | 2012-12-21 | 2019-07-02 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
BR112015020650A2 (pt) | 2013-02-27 | 2017-07-18 | Epitherapeutics Aps | inibidores de histona demetilases |
HUE034906T2 (hu) | 2013-03-15 | 2018-03-28 | Quanticel Pharmaceuticals Inc | Hiszton-demetiláz inhibitorok |
WO2015035062A1 (fr) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Composés antiprolifératifs |
EP3126345A1 (fr) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibiteurs d'histones déméthylases |
-
2015
- 2015-08-26 EA EA201790154A patent/EA201790154A1/ru unknown
- 2015-08-26 AU AU2015306662A patent/AU2015306662A1/en not_active Abandoned
- 2015-08-26 KR KR1020177006855A patent/KR20170040805A/ko unknown
- 2015-08-26 SG SG11201701182VA patent/SG11201701182VA/en unknown
- 2015-08-26 MX MX2017002451A patent/MX2017002451A/es unknown
- 2015-08-26 CA CA2957947A patent/CA2957947A1/fr not_active Abandoned
- 2015-08-26 MA MA040470A patent/MA40470A/fr unknown
- 2015-08-26 US US14/836,397 patent/US9802941B2/en active Active
- 2015-08-26 JP JP2017510881A patent/JP2017526675A/ja not_active Withdrawn
- 2015-08-26 WO PCT/US2015/046921 patent/WO2016033169A1/fr active Application Filing
- 2015-08-26 AR ARP150102728A patent/AR101692A1/es unknown
- 2015-08-26 TW TW104127904A patent/TW201625536A/zh unknown
- 2015-08-26 EP EP15759595.0A patent/EP3186238A1/fr not_active Withdrawn
- 2015-08-26 CN CN201580046345.3A patent/CN107074807A/zh active Pending
- 2015-08-26 BR BR112017003442A patent/BR112017003442A2/pt not_active Application Discontinuation
-
2017
- 2017-01-30 IL IL250355A patent/IL250355A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2957947A1 (fr) | 2016-03-03 |
AU2015306662A1 (en) | 2017-03-09 |
EA201790154A1 (ru) | 2017-08-31 |
US9802941B2 (en) | 2017-10-31 |
CN107074807A (zh) | 2017-08-18 |
JP2017526675A (ja) | 2017-09-14 |
IL250355A0 (en) | 2017-03-30 |
EP3186238A1 (fr) | 2017-07-05 |
BR112017003442A2 (pt) | 2017-11-28 |
MX2017002451A (es) | 2017-05-23 |
SG11201701182VA (en) | 2017-03-30 |
AR101692A1 (es) | 2017-01-04 |
US20160102096A1 (en) | 2016-04-14 |
WO2016033169A1 (fr) | 2016-03-03 |
TW201625536A (zh) | 2016-07-16 |
KR20170040805A (ko) | 2017-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40470A (fr) | Composés et procédés d'inhibition des histones déméthylases | |
PH12018501096A1 (en) | Modulators of chemokine receptors | |
AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
MX2018006148A (es) | Inhibidores de cxcr2. | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
MX2020001278A (es) | Sintesis de compuestos de carbamoilpiridona policiclica. | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201790983A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
MX2017002214A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
MX2020003020A (es) | Compuestos de aminocarbonilcarbamato. | |
CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
MX2016015543A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno. | |
TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
BR112016027455A2 (pt) | moduladores ppar | |
MX2017010901A (es) | Colorantes de acido trisazo. | |
IN2014MU01192A (fr) | ||
IN2014MU00195A (fr) | ||
IN2014MU00194A (fr) | ||
IN2014MU01196A (fr) | ||
MX2021015198A (es) | Peptidos toxicos activados artificialmente. | |
IN2014MU00858A (fr) | ||
IN2014MU00069A (fr) |